



JUNE 4-7, 2018

WALLONIA@BIO, BOSTON, USA

BELGIAN PAVILION, BOOTH #1743

VERSION 1.3

\ TABLE OF CONTENTS

INTRODUCTION	
WALLONIA COMPANIES AT BIO 2018 BOSTON	1
ORGANIZERS WALLONIA DELEGATION AT BIO 2018	16
PARTNERS WALLONIA DELEGATION AT BIO 2018	19
TRADE & INVESTMENT OFFICES	21

\ INTRODUCTION

Innovation is at the core of the life sciences sector and Belgium has a track record of developing ingenious ways to improve the quality of life of millions of people worldwide.

Not only **extensive life sciences facilities** support this high-level technology industry but also **financial benefits for R&D companies, international collaborations** that guarantee regular cash flow, **world known educational systems**, a **promising product pipeline**, and **Belgium's unique central location in Europe**.

Belgium concentrates more than **300 life sciences companies** with biotech activities on a small territory (30,528 km²). In total, the life sciences sector employs **more than 30,000 people** (low bound estimation that does not take into account indirect employment generated by the sector). The majority of the companies is related to **healthcare**, but Belgium also has a strong representation of **agricultural** and **industrial biotech companies**.

The growing life sciences sector gathers **8 main Belgian universities, 19 research parks** and **23 incubators, research institutes, academic hospitals, and clinical research organizations**. Biotech companies have access to **more than 500,000 square feet of highly flexible infrastructure**.

Additional assets of Belgium includes: a **supportive regulatory and political environment**, a **highly qualified and productive workforce**, a **competitive tax environment** especially for research companies, a **prominent location** and an **excellent logistical and business infrastructure**.

WALLONIA COMPANIES AT BIO 2018, BOSTON

ABBVIE	1
AMPLYCELL	1
ANDAMAN7	2
BELGIAN VOLITION	2
BIOPARK ULB CHARLEROI	3
BONE THERAPEUTICS	3
CER GROUPE	4
CIDE-SOCRAN	4
CSM	5
DELPHI GENETICS	5
EUROSCREEN FAST	6
GSK	6
IPS USA (PART IF GROUP IPS)	7
IT4IP	7
KANEKA EUROGENTEC	8
KIOMED PHARMA	8
LIEU TTOS NETWORK	9
MASTHERCELL	9
MITHRA PHARMACEUTICALS	10
NOVADIP BIOSCIENCES	10
ONCODNA	11
PDC*LINE PHARMA	11
PROMETHERA BIOSCIENCES	12
SYNGULON	12
UCB	13
UNIVERCELLS	13
UNIVERSITY OF MONS	14
UNIVERSITY OF NAMUR	14
WBC INCUBATOR (BIOTECH COACHING SA)	15
XPRESS BIOLOGICS	15
AQUILON PHARMACEUTICALS	16
BONE VET	16

NAVIGATION TIPS :

Click on the company name to access the company profile.

To return to the company Index, click on the [WALLONIA@BIO USA] footer

WALLONIA COMPANIES AT BIO 2018, BOSTON, (Continued)

TOPVAC	17
CURAVAC	17
DROPER	18
I TECH INCUBATOR	18
MYDATA TRUST	19
OGEDA/EUROSCREEN FAST	19
OPEN WORLDWIDE INNOVATION NETWORK	20
SAGITTA BIOTECH	20
NEUROPATH	21
SPECTRALYS BIOTECH	21
THEODORUS FUND	22

NAVIGATION TIPS :

Click on the company name to access the company profile.

To return to the company Index, click on the [WALLONIA@BIO USA] footer

WHAT ARE YOU LOOKING FOR?

BIOTECHNOLOGY - THERAPEUTICS

ABBVIE	1
AMPLYCELL	2
BONE THERAPEUTICS	3
DELPHI GENETICS	5
MASTHERCELL	9
NOVADIP BIOSCIENCES	10
ONCODNA	11
PDC*LINE PHARMA	11
PROMETHERA BIOSCIENCES	12
SYNGULON	12
WBC INCUBATOR	15
BONE VET	16
CURAVAC	17
OGEDA/EUROSCREEN	19
SAGITTA BIOTECH	20

MEDICAL TECHNOLOGY

ANDAMAN7	2
BELGIAN VOLITION	2
CSM	5
IT4IP	7
MITHRA PHARMACEUTICALS	10
UCB	13
TOPVAC	17
DROPER	18
NEUROPATH	21

NAVIGATION TIPS :

Click on the company name to access the company profile.

To return to the company Index, click on the [WALLONIA@BIO USA] footer

WHAT ARE YOU LOOKING FOR?

PHARMA

GSK	6
KIOMED PHARMA	8
AQUILON PHARMACEUTICALS	16

PROFESSIONAL SERVICES & CONSULTING

CIDE-SOCRAN	4
IPS USA CORPORATION	7
I TECH INCUBATOR	18
MYDATA TRUST	19
THEODORUS FUND	22

PUBLIC/NON-PROFIT ORGANISATIONS

BIOPARK/ULB CHARLEROI	3
LIEU TTOS NETWORK	9
UNIVERSITY OF MONS	14
UNIVERSITY OF NAMUR	14
OWIN	20

R&D SERVICES

KANEKA EUROGENTEC	8
XPRESS BIOLOGICS	15
SPECTRALYS BIOTECH	21

NAVIGATION TIPS :

Click on the company name to access the company profile.

To return to the company Index, click on the [WALLONIA@BIO USA] footer

\ ABBVIE

abbvie

Avenue Einstein 14 • BE-1300 WAVRE
T +32 10 47 78 11
www.abbvie.com

Delegate: **Tineke VAN HOOLAND**, External Affairs Director AbbVie BeLux •
tineke.vanhooland@abbvie.com

AbbVie (2013) is a research-driven, patient-focused leading global biopharmaceutical company, capable of achieving sustainable top-tier performance with a consistent stream of innovative new medicines that raise the standard of care for some of the world's most critical medical challenges. We do more than treat diseases. We aim to make a remarkable impact on people's quality of life by investing in health. Passion and responsibility of 29.000 people, in more than 175 countries.

Category: Biotechnology - Therapeutics

\ AMPLYCELL



Avenue Hippocrate
BE-4000 LIEGE

T +32 497 77 31 77
www.amplycell.com

Delegate: **Geoffrey HOLSBECK**, CEO • geoffrey.holsbeck@amplycell.com

At **AmplifyCell** we have developed the AMPLY™ Technology that makes it possible to produce biomolecules and drugs at affordable cost. We directly address the holy cow of BioPharma industry, their cell lines used for their bioproduction, making them up to 10x more profitable in terms of yield and even more in term of financial profit. AMPLY™ Technology is based on physical stimulation treatments that activate cell line metabolism and productivity in a permanent way. By applying on cell lines such as Chinese Hamster Ovary (CHO), Human Embryonic Kidney (HEK293) and hybridomas, it allows cost-effective and efficient GMP manufacturing of recombinant proteins, difficult-to-express New Biological Entities, Biosimilars drugs and viral vectors.

Category: Biotechnology - Therapeutics

\ ANDAMAN7



Rue Wagner 127 • BE-4100 SERAING
T +32 4 330 37 30
b2b@andaman7.com
www.andaman7.com

Andaman7 mobile solution improves disease and outcomes management. Our technology integrates easily in the care workflow, and can be comfortably used by patients anytime, anywhere

- providing HCPs with quick and accurate results,
- improving patient quality of life and outcomes,
- providing partners with cost-effective solutions and underlying evidence.

Andaman7 creates value in the following areas:
RWE & outcomes data • Beyond the pill solution
• Disease management • Clinical trials

Category: Medical Technology

Delegates: **Vincent KEUNEN**, CEO • vincent.keunen@andaman7.com
Philippe LEMMENS, COO • philippe.lemmens@andaman7.com
David LEVESQUE, Sr. Director Business Development • david.levesque@andaman7.com

\ BELGIAN VOLITION



Rue Phocas Lejeune 22 • BE-5032 ISNES
T +32 81 40 79 10
www.volitionrx.com

Volition is developing blood based tests for cancer using its proprietary Nucleosomics® immunoassay technology platform. Our simple, accessible and cost effective nucleosome quantification (Nu.Q™) approach utilises global epigenetic epitope profiles from cell free nucleosomes to answer specific clinical questions. **Volition** is developing a simple blood test for colorectal cancer screening employing the Nu.Q™ technology which is available in kits and as a service for Research Use Applications.

Category: Medical Technology

Delegates: **Gaetan MICHEL**, CEO Belgian Volition • g.michel@volitionrx.com
Mark ECCLESTON, Business Development Director • m.eccleston@volitionrx.com

\ BIOPARK ULB CHARLEROI



8 rue Adrienne Bolland • BE-6041 CHARLEROI
T +32 2 650 98 69
www.biopark.be

Delegate: **Dominique DEMONTE**, Director of the Biopark ULB Charleroi • ddemonte@ulb.ac.be

Created by the **Université Libre de Bruxelles (ULB)** in 1999, the **Biopark** is located close to the Brussels South Charleroi Airport in Belgium. The **Biopark** is today the playground of more than 1300 people working in 3 research institutes, 47 companies, an incubator and a training center. The presence of all these players on the same site is a valuable asset and the **Biopark** has thus become a top location for Research, Companies and Partnerships between universities, private and public institution.

Category: Public/Non-Profit Organisations

\ BONE THERAPEUTICS



Rue Auguste Piccard 37 • BE-6041 GOSELIES
T +32 71 12 10 00
info@bonetherapeutics.com
www.bonetherapeutics.com

Delegates: **Thomas LIENARD**, CEO
Caroline QUOILIN, Business Development Manager •
caroline.quoilin@bonetherapeutics.com

Bone Therapeutics is a leading cell therapy company addressing high unmet medical needs in the field of orthopaedics and bone diseases. We have a broad, diversified portfolio of bone cell therapy solutions in clinical development across a number of disease areas targeting markets with large unmet medical needs and limited innovation. Our technology is based on a unique, proprietary approach to bone regeneration which turns undifferentiated stem cells into “osteoblastic”, or bone-forming cells.

Category: Biotechnology - Therapeutics

\ CER GROUPE



Rue de la Science 8
BE-6900 MARCHE EN FAMENNE
T +32 84 22 02 11
info@cergroupe.be
www.cergroupe.be

Delegate: **François CÔTE**, Project Manager & Business Developer • f.cote@cergroupe.be

CER Groupe is a Belgian Registered Research Center providing services, products and research in veterinarian, biotech and biomedical areas.

- Preclinic
Preclinical models in cell therapy, cancerology, infectiology and immunology - Small and large animals - Regulatory and non-regulatory studies in SPF/SOPF and ABSL3 facilities - GLP-compliant CRO - Analytical support: ELISA, FACS, PCR, ...
- Biomanufacturing
Custom antibodies/kits development - Antigen design - Virus/cell production

Category: R&D Services

\ CIDE-SOCRAN



Rue Lambert Lombard 3 • BE-4000 LIEGE
T +32 499 38 31 19
www.cide-socran.be

Delegate: **Bertrand JOIRET**, Project Manager • bjoiret@cide-socran.be

Cide-Socran is a consultancy office specialized in the support of life sciences companies. Our competences cover different areas: medicinal products, medical devices, diagnostics, support services,... **Cide-Socran** provides services on commercial and financial matters, especially on market analysis, business plans, financial planning, fundraising and project management. The goal of **Cide-Socran** is to reduce the financial and commercial uncertainty linked to the design and launch of new products.

Category: Professional Services & Consulting

\ CSM



Since 1997, **CSM** is providing innovative solutions to meet the complex clinical supply challenges pharmaceutical and biotechnology companies face. With two facilities in Post-Brexit EU and three in the US, **CSM** is committed to ensuring clinical trials are a success, regardless of size or scope, from Phase I to Phase IV projects.

Category: Medical Technology

Rue Granbonpré 11 • BE-1435 MONT-SAINT-GUIBERT
T +32 10 23 74 44
csmrequesteu@csmondemand.com
www.csmondemand.com

Delegate: **David FONTAINE**, VP Global Sales & Marketing • dfontaine@csmondemand.com

\ DELPHI GENETICS



Delphi Genetics is a biotech company providing innovative services and technologies in the field of pDNA production, recombinant proteins production and antibody development. The StabyExpress® technology increases the yield of recombinant protein or pDNA production in E. coli without the use of antibiotics and is also applied to DNA vaccines engineering and innovative gene therapy. We have facilities for production of plasmid DNA with different quality grades including GMP and High quality.

Category: Biotechnology - Therapeutics

Rue Antoine de Saint Exupéry 5
BE-6041 CHARLEROI
T +32 71 25 10 00
delphigenetics@delphigenetics.com
www.delphigenetics.com

Delegate: **Thierry VAN REETH**, Scientific & Sales Manager • tvanreeth@delphigenetics.com

\ EUROSCREEN FAST



Rue Adrienne Bolland 47 • BE-6041 GOSSELIES
T +32 71 34 85 08
www.euroscreenfast.com

Delegate: **Laurent MEEUS**, Business Unit Director, Euroscreen FAST •
lmeeus@euroscreenfast.com

Euroscreen FAST, provides in vitro screening and assay development services on GPCR. For more than 20 years, **Euroscreen FAST** has built the largest catalog of recombinant GPCR assays on the market, with over 900 assays available on human and animal model receptors. We also offer custom-development of new cell lines and assays, to meet your specific validation criteria. Our expertise is also well-illustrated by our unique GPCR deorphanization platform with a track record of 17 successful programs.

Category: R&D Services

\ GSK



Rue De L'Institut 89 • BE-1330 RIXENSART
T +32 2 656 81 11
vaccinespartnering@gsk.com
www.gsk.com

Delegate: **Philippe DENOEL**, Head of External R&D

GSK is one of the world's leading vaccine companies, involved in vaccine research, development and production. We have 14 vaccines in development and our broad portfolio of 41 vaccines prevent illnesses such as hepatitis A, hepatitis B, diphtheria, tetanus, whooping cough, measles, mumps, rubella, polio, typhoid, influenza and bacterial meningitis. Globally, we have more than 16,000 people working to deliver more than 2 (2.3) billion vaccines every day, to people in 166 countries.

Category: Pharma

\ IPS USA CORPORATION (PART OF GROUP IPS)



7905 Browning Road, Suite 214
08109 PENNSAUKEN • USA
T +1 856 438 62 32
eca@group-ips.com
www.group-ips.com

Delegates: **Karel DE SWERT**, General Manager • kds@group-ips.com
Ryan CRONIN, Project Engineer • rcr@group-ips.com

IPS is specialized in the management of industrial projects acting as Owner's Representative fully integrated in the Owner's project team. We cover all services from the initial definition of the project over the project preparation (investment analysis, permitting, procurement, financing), the project realization (project management, time schedule, cost control, safety coordination, recruitment) till operation of the plant (interim management).

Category: Professional Services & Consulting

\ IT4IP



Avenue Jean-Etienne Lenoir, 1
1348 Louvain-la-Neuve (Belgium)
Mail: contact@it4ip.be
Phone: +32(0)10 226114
Fax: +32(0)10
www.it4ip.be225661

Delegate: Rodais CHANSON, Business Development Assistant - chanson@it4ip.be

IT4IP's competences and activities focus on track-etched polymer membrane filters, and on their manufacturing, processing and conversion from raw polymer films up to finished products tailored to customer applications. All our activities are strengthened by a large expertise in polymer science and cell biotechnology that enables the design and production of innovative products and devices for specialized applications (for e.g. healthcare, diagnosis, energy, ...).

\ KANEKA EUROGENTEC



Rue Bois Saint-Jean 5 • BE-4102 SERAING
T +32 4 372 74 00
info@eurogentec.com
www.secure.eurogentec.com

Kaneka Eurogentec is a leading provider of custom products for Life Science Research, in vitro Diagnostic and Therapeutic applications. Products are manufactured according to ISO 9001, ISO 13485 or cGMP requirements for biotech and large pharmaceutical companies around the world. Our biologics offering includes full-service gene to injectable biopharmaceutical contract manufacturing of products for clinical and commercial use. Eurogentec was founded in 1985 and employs 350 people worldwide.

Category: R&D Services

Delegates: **Pascal BOLON**, Biologics Commercial Director • p.bolon@eurogentec.com
Vincent DEHOUSSE, Biologics Account Manager • v.dehousse@eurogentec.com
Jean Michel SCHAUS, Biologics Account Manager • j.m.schaus@eurogentec.com

\ KIOMED PHARMA



KiOmed Pharma designs and develops innovative osteoarthritis treatments and aesthetic medical devices based on proprietary animal-free chitosan biomaterials.

Category: Pharma

Rue Haute Claire 4 • BE-4040 HERSTAL
T +32 4 228 80 40
www.kiomedpharma.com

Delegate: **Houtai CHOUANE**, CEO • houtai.choumane@kiomedpharma.com

\ LIEU TTOs NETWORK



LIEU is the network of TTOs of the Belgian French-speaking universities and higher education institutions. LIEU connects research and business through collaborations, IP management and tech transfer.

Category: Public/Non-Profit Organisations

Passage des Déportés 2 • BE-5030 GEMBLoux

T +32 65 37 47 78

www.reseaulieu.be

Delegates: **Marlène GENLAIN**, Technology Transfer Officer – Life Sciences •
marlene.genlain@umons.ac.be
Virginie BOURGUIGNON, Technology Transfer Officer – Life Sciences •
virginie.bourguignon@unamur.be

\ MASTHERCELL



MaStherCell is a global and leading Contract Development and Manufacturing Organization (CDMO) on a mission to deliver optimized process industrialization capacities to cell therapy organizations, and fast track the arrival of their therapies onto the market. MaStherCell has a state of the art expertise in the immunotherapy field (CAR-T, TCR and others) and operates sites in Europe, Israel and Korea.

Category: Biotechnology - Therapeutics

Rue Auguste Piccard 48 • BE-6041 GOSSELIES

T +32 71 15 96 40

www.masthercell.com

Delegates: **Denis BEDORET**, General Manager • denis.bedoret@masthercell.com
Romain DE RAUVILLE, Business Development Manager •
romain.derauville@masthercell.com

\ MITHRA PHARMACEUTICALS



Rue Saint-Georges 5 • BE-4000 LIEGE
T +32 476 96 54 59
www.mithra.com

Delegate: **Jean-Manuel FONTAINE**, Head of External Affairs • jmfontaine@mithra.com

Mithra is dedicated to providing innovation and choice in women's health. Its two lead development candidates - a fifth generation oral contraceptive, Estelle®, and a next generation hormone therapy, Donesta®- are built on **Mithra's** unique natural estrogen platform, E4 (Estetrol). **Mithra** also develops, manufactures and markets complex therapeutics (rings, IUD, implant) and offers partners a complete spectrum of R&D and specialist manufacturing. Founded in 1999, spin off university of Liege-Belgium.

Category: Pharma

\ NOVADIP BIOSCIENCES



Rue Granbonpré 11
BE-1435 MONT-SAINT-GUIBERT
T +32 10 77 92 20
www.novadip.com

Delegate: **Jean-François POLLET**, Co-founder and CEO • jean-francois.pollet@novadip.com

Novadip is a biopharmaceutical company founded to develop innovative stem cell-based therapies adapted for regenerative medicine. **Novadip** pioneers the growth of 3-D tissues derived from adipose-derived stem cells to regenerate hard and soft tissues. NVD-001 and NVD-003 are revolutionary and ready-to-use 3D osteogenic structures that can be modelled to fill large and small bone defects. NVD-002 is a tissue engineering product for dermal reconstruction, designed to avoid formation of painful scars.

Category: Biotechnology - Therapeutics

\ ONCODNA



Rue Louis Breguet 1 • BE-6041 GOSSELIES
T +32 71 18 35 00
infos@oncodna.com
www.oncodna.com

Delegates: **Jean-Pol DETIFFE**, CEO • jp.detiffe@oncodna.com

Christophe VAN HUFFEL, Business Developer Pharma • cvh@oncodna.com

OncoDNA's aim is to provide medical innovations based on targeted sequencing or complete sequencing of tumor genomes, in order to assist medical doctors in their treatment choices and/or provide better monitoring of the evolution of patient tumors. The ambition of the company is to rapidly become a European reference for personalized analysis in oncology, based on the analysis of tumor's DNA from patients.

Category: Biotechnology - Therapeutics

\ PDC* LINE PHARMA



CHU - Tour 5 (B34) - GIGA, Avenue de l'Hôpital 11 • BE-4000 LIEGE
T +32 474 05 78 66
www.pdc-line-pharma.com

Delegate: **Eric HALIOUA**, President & CEO • E.halioua@pdc-line-pharma.com

Founded in 2014, **PDC*line Pharma** is a biotech company that develops a new class of potent, scalable and off-the-shelf therapeutic cancer vaccines based on a proprietary allogeneic cell line of Plasmacytoid Dendritic Cells (PDC*line). Based on a first-in-human phase I study in melanoma, **PDC*line Pharma** focuses on the development of a candidate for lung cancer (PDC*lung). The company regroups a team of 16 peoples with a seasonal management team and raised more than 10M€ in equity and loans.

Category: Biotechnology - Therapeutics

\ PROMETHERA BIOSCIENCES



Rue Granbonpré 11
BE-1435 MONT-SAINT-GUIBERT
T +32 10 39 43 00
contact@promethera.com
www.promethera.com

Delegates: **Henrik LUESSEN**, CBO • hendrik.luessen@promethera.com
Pascale JORDAN, Director Business Development – External Evaluation •
pascale.jordan@promethera.com

Promethera Biosciences is a global innovator in liver cell-based medicines whose mission is to help patients overcome acute and chronic liver diseases. Our lead clinical program, derived from our patented cell technology platform HepaStem, is designed to benefit from its immunomodulatory and anti-fibrotic properties. We are a team of international experts operating out of R&D and GMP facilities in Mont-Saint-Guibert, Belgium, and Durham, NC, USA.

Category: Biotechnology - Therapeutics

\ SYNGULON



Rue du Bois Saint-Jean 15/1
BE-4102 SERAING
T +32 4 290 55 45
contact@syngulon.com
www.syngulon.com

Delegate: **Guy HELIN**, CEO • ghelin@syngulon.com

Syngulon introduces genetic technologies (US Patent 9,333,227 + NEW patents filed in 2017) on the control of microorganism. The patent is based on the use of bacteriocin/immunity in any bacteria, yeast or algae for controlled growth of microorganisms.

Technology can be used by any company using microbial fermentation looking for key issues Gene containment/Yield increase/Contamination prevention/Genetic drift/Antibiotic-free selection.

Non-exclusive licensing available in all field of use.

Category: Biotechnology - Therapeutics

\ UCB



Allée de la Recherche 60 • BE-1070 BRUSSELS
T +32 2 559 99 99
contactucb@ucb.com
www.ucb.com

Delegate: **Didier MALHERBE**, Vice President Public Affairs UCB & General Manager UCB Belgium • didier.malherbe@ucb.com

UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With more than 7500 people in approximately 40 countries, the company generated revenue of € 4.5 billion in 2017. **UCB** is listed on Euronext Brussels (symbol: **UCB**).

Category: Pharma

\ UNIVERCELLS



Rue Auguste Piccard 48 • BE-6041 GOSSELIES
T +32 2 318 83 48
www.univercells.com

Delegates: **Mathias GARNY**, Director of Business Development • m.garny@univercells.com
Vincent Tallier, Sales Manager • v.tallier@univercells.com

Univercells is a company developing innovative manufacturing processes with the objective of significantly reducing the cost of goods of biological drugs (mAbs, Vaccines, recombinant proteins). Our processes are using low-footprint systems, incorporating high-density bioreactors operated in perfusion with in line purification, leading to very low cost of goods. **Univercells** offers process development collaboration or complete manufacturing packages including vaccine or biosimilar licenses.

Category: Biotechnology - Therapeutics

\ UNIVERSITY OF MONS



Place du Parc 20 • BE-7000 MONS
T +32 65 37 47 78
www.umons.ac.be

Delegate: **Marlène GENLAIN**, Technology Transfer Officer – Life Sciences •
marlene.genlain@umons.ac.be

Research at the **University of Mons (UMONS)** relies on more than 800 researchers spread across 10 research institutes. They focus their efforts on unifying themes covering three major areas of current research, life sciences and health, science and technology and human and social sciences, thus meeting recognised societal needs and giving them increased international visibility. These Institutes are supported by the **UMONS KTO** who is an active member of the LIEU Network.

Category: Public/Non-Profit Organisations

\ UNIVERSITY OF NAMUR



Rue de Bruxelles 61 • BE-5000 NAMUR
T +32 81 72 57 07
www.unamur.be

Delegate: **Virginie BOURGUIGNON**, Technology Transfer Officer – Life Sciences •
virginie.bourguignon@unamur.be

The **University of Namur** conducts many research projects often interdisciplinary and involving both companies and other academic institutions. In the field of Life Sciences, some of our core competencies are:

- Nanoparticles toxicity and functionalization
- Chemoresistance and radiosensitizing agents
- Thrombosis and hemostasis
- Osteoarticular and skin pathology
- Infectiology

UNamur is also a member of the LIEU Network, the collaborative network of KTOs in Fédération Wallonie-Bruxelles.

Category: Public/Non-Profit Organisations

\ WBC INCUBATOR (BIOTECH COACHING SA)



Avenue de l'Hôpital 11 – B34 • BE-4000 LIEGE
T +32 4 246 51 10
contact@wbc-incubator.be
www.wbc-incubator.be

Delegates: **Serge PAMPFER**, CEO • pampfer@wbc-incubator.be
Hélène SAGNES-LALANNE, Business Coach • lalanne@wbc-incubator.be
Franck TOUSSAINT, International Business Coach • toussaint@wbc-incubator.be

WBC finances and guides healthcare companies through their phases of creation and industrial maturation over a period of six years in the French-speaking region of Wallonia. Products and services developed by these companies are mostly innovative therapeutics, diagnostics or devices (biotech and medtech). **WBC** support is also available for e-health solutions as well as for selected nutrition and environment applications.

Category: Biotechnology - Therapeutics

\ XPRESS BIOLOGICS



Avenue du Parc Industriel 89
BE-4041 MILMORT
T +32 4 346 00 20
www.xpress-biologics.com

Delegates: **Marc DAUKANDT**, Chief Executive Officer • m.daukandt@xpress-biologics.com
Christian RODRIGUEZ, Chief Operation Director • ch.rodriguez@xpress-biologics.com

Xpress Biologics is a contract development organization specialized in the production of Biologics, proteins and DNA, for preclinical applications specific to the therapeutic and diagnostic markets. Its mission is to enable the transition of the projects from R&D to clinical manufacturing. The production scale (from 100 mg to 50 g) and the quality of the biologics (R&D and GLP grade material) are adapted for in vitro and in vivo preclinical validation of the biologics.

Category: R&D Services

\ AQUILON PHARMACEUTICALS



Rue de Rotterdam, 3
4000 Liège Belgium
T +32 4 274 32 30
www.wbc-incubator.be/en/incubated/aquilon-pharma

Delegate: **Ludivine PETIT** - lpetit@aquilonpharma.com

Aquilon is a specialty pharmaceutical company engaged in the development of drugs & improving the treatment of pulmonary diseases using the Value Added Medicines model. Nowadays, new geographical markets appear in the emerging economies due to pollution once again. Aquilon Pharma intends to create value added medicines by combining the cyclodextrin with the most efficient active molecules and the best-known device available on the market. The carrier can be added to every treatment available on the market to improve their efficacy.

\ BONE VET



Rue Piccard
6041 Gosselies Belgium
T +32 47 31 50 94

Delegate: **Julie WINAND**, Preclinical & Production Director - julie.winand@bonevet.eu

BONE VET is specializing in bone/joint diseases, orthopedics, rheumatology, inflammation and metabolism in pets, and more specifically in dogs.

\ TOPVAC

TOPVAC

TOPVAC is a spin-off of UCL Louvain Drug Research Institute, with the aim of developing and valorizing a new DNA (pTOP) vaccination technology. By its polyvalent nature, the pTOP technology opens up numerous avenues leading to various applications in therapeutical vaccination .
From a regulatory standpoint, products currently under development will be classified as drugs used in genetical therapy .

B-1348 Louvain-la-Neuve Belgium
T +32 2 764 73 09

Delegate: Véronique PRÉAT, Professor - veronique.preat@uclouvain.be

\ CURAVAC



CURAVAC Europe
Avenue de Villefranche, 80
B – 1330 Rixensart Belgium
www.curavac.com

CuraVac was created to develop the medical and commercial potential of a newly discovered technique for the production of therapeutic vaccines for the treatment of autoimmune diseases.

Founded by Belgian MD Dr. Stéphane Huberty, who himself suffered from myasthenia gravis, CURAVAC is developing a vaccine to be tested on humans suffering from MG. While a not widely known orphan disease, MG affects more than one in five thousand and its pathology is clearly understood, making it an excellent development model.

Further CuraVac therapeutic vaccines will be developed for the treatment of other autoimmune diseases, including multiple sclerosis, diabetes, rheumatoid arthritis and systemic lupus erythematosus. In total, autoimmune diseases afflict more than five percent of western population.

Delegate: Stéphane HUBERTY, CEO - mail@curavac.com

\ DROPER



Lieu dit "Maison Bois", 1
4877 Olne Belgium
T +1(803)422 0161
www.droper.be

DROPER is the first portable and totally mechanical infusion pump delivering a constant flow with no external energy source required. Reliable, easy-to-use, Droper is particularly suitable to all emergency situations with need of IV-drip. This infusion pump uses mechanical compression without need of pole, electricity, batteries, or physical intervention. Autonomous, it allows the rescuer to focus on medical care. Droper can be used in various positions, in any confined situations (caving, collapsed buildings, mountain rescues...) and even in gravity-free situation.

Delegate: Jean-Louis VANDERSTRAETEN, Manager US Operations - jl@SCbCS.us

\ I TECH INCUBATOR

I TECH INCUBATOR

Strategically located in the heart of the BIOPARK Charleroi Brussels South, I TECH INCUBATOR offers industry leading facilities on very flexible terms. The BIOPARK's high concentration of biotech activity makes it the ideal location for expanding your business into Europe.

Rue Auguste Piccard 48,
6041 Charleroi Belgium
T +32 (0)71 20 28 89
www.igretec.com

Delegate: Marie BOUILLEZ, General Manager - marie.bouillez@i-tech-incubator.be

\ MYDATA TRUST



Business Innovation Centre de Mons
Parc Scientifique Initialis
Rue René Descartes, 2
7000 Mons Belgium
T +32 493 09 97 04
www.mydata-trust.eu

MyData-TRUST's main objective consists in supporting the Life Sciences Industry in leveraging their compliance related to Data Protection, thanks to a multi-disciplinary team including data privacy lawyers, IT security specialists and pharmaceutical subject matter experts. This unique combination of skills and knowledge allows to quickly and efficiently address their clients' needs in providing a range of services and solutions aligned with both Pharmaceutical R&D and GDPR requirements. MyData-TRUST proposes:

- Professional consulting services : data processing compliance assessment and corrective actions plan;
- End-to-end solutions to guarantee the patients privacy and the compliance with Regulation.

Delegate: Gautier SOBCZAK, Business Development Executive - g.c.sobczak@mydata-trust.com

\ OGEDA/EUROSCREEN FAST



Rue Adrienne Boland 47
GOSELIES 6041 Belgium
T +32 71 348 500
www.euroscreenfast.com

Euroscreen FAST, the Services Unit of Ogeda SA, provides in vitro screening and assay development services on G protein-coupled receptors (GPCR). Using its expertise of more than 20 years in the field, Euroscreen FAST has built one of the largest catalogue of recombinant GPCR assays on the market, with over 900 functional and binding assays available on human and animal model receptors, and more to come. These assay can be used for HTS, Hit-to-Lead and Lead Optimization functional profiling with pre-set or custom panels. We also offer custom-development of new cell lines and assays to meet your specific validation criteria, for a moderate fee. These past 2 years, 70 new receptors have been added to the catalogue. Our expertise is also well-illustrated by our unique GPCR deorphanization platform with its first-in-class track record of 17 successful programs, some of which were sponsored by high profile partners like Novartis or Merck KGaA, and generated patented IP.

Delegate: Laurent MEEUS, Business Unit Director - lmeeus@euroscreenfast.com

OPEN WORLDWIDE INNOVATION NETWORK



Boulevard Baudouin 12 • BE-1000 BRUSSELS
T +32 474 92 64 18
www.openiwin.com

Delegates : **Amaëlle HAULET**, Executive Director • amaelle.haulet@openiwin.com
Philippe LACHAPPELLE, Director Business Development and Strategic Partnerships - AWEX
Tel : +32 2 421 86 79 • p.lachapelle@awex.be

OWIN - Open Worldwide Innovation Network is a Membership Association of Universities, TTOs and Trade Agencies encouraging a global culture of innovation and entrepreneurship.

OWIN fosters win-win opportunities and helps companies grow faster in its members markets (Australia, Belgium, China and the USA) by assessing technologies, identifying commercial and strategic partnerships, coordinating joint-ventures and much more!

Category: Public/Non-Profit Organisations

SAGITTA BIOTECH



Manage Belgium
T +32 475 429313
www.sagittabiotech.com

Sagitta Biotech is developing innovative cancer immunotherapies based on oncolytic viruses and checkpoint inhibitors.

Delegate: Benjamin DAMIEN, CEO - b.damien@sagittabiotech.com

\ NEUROPATH



Chemin du Cyclotron 6,
1348 Louvain-La-Neuve, Belgium
T +32 472 74 16 71
remedia.be/neuropath

NeuroPath is developing a secure software package to analyze functional mobility and sentiment data to empower patients who may be experiencing symptoms or signs of neurological disease.

NeuroPath's core algorithms are created and trained from user generated health data through a host of different devices, e.g. Physical, Medical Devices, Body Functions, Emotional, Environmental, Medical Records, Motion Capture.

NeuroPath's core algorithms are constantly interacting with patient generated data for multiple purposes.

Patients, athletes, and consumers can use this interface to track their health and wellness through an interactive IoT framework

Delegate: Benoît TAS, CEO & Co-Founder - benoit.tas@levantas.be

\ SPECTRALYS BIOTECH



Bld du Triomphe, accès 2,
CP206/2 Building BC, Level 4, Room 1C4102
Bruxelles 1050 Belgium
t +32 497056708
<https://spectralysbiotech.com/>

Spectralys Biotech is a spin-off from the Université libre de Bruxelles offering innovative analytical solutions for biomolecules based on our unique expertise leveraging infrared spectroscopy (FTIR). Over the last 10 years, our team has developed the expertise (patent filed), through one single measurement, to obtain information on 4 key parameters concerning protein structure and quantification:

- (i) higher order structure;
- (ii) composition and quantification of post-translational modifications (glycosylations, phosphorylations,...);
- (iii) overall protein concentration and
- (iv) quantification of key excipients such as detergents , stabilizing agents or lipids.

These methods can be transferred to your production site, ensuring real-time and in-process information about key characteristics of your production batches.

Delegate: Allison DERENNE, Spin-off Developer - allison.derenne@spectralysbiotech.com

\ THEODORUS FUND



Allée de la Recherche 12
1070 Brussels Belgium
T +32 2 529 58 11
www.theodorus.be/

THEODORUS FUND is a spin-off fund created by the Université Libre de Bruxelles with the aim of maximizing the value of research & innovation.

Delegate: Lofti Yelles CHAOUICHE, Partner
Françoise MAGERMAN - francoise.magerman@ulb.ac.be

ORGANIZERS

WALLONIA DELEGATION AT BIO 2018

BIOWIN

WALLONIA EXPORT-INVESTMENT AGENCY

(AWEX) WALLONIA-BRUSSELS INTERNATIONAL

\ BIOWIN



Maison de l'Industrie Technologique
BE-6041 GOSSELIES
T +32 71 91 92 85
contact@biowin.org
www.biowin.org

Delegates: **Sylvie PONCAHUT**, Managing Director • sylvie.ponchahut@biowin.org
Laurence TIMMERMANS, Head of International Affairs •
laurence.timmermans@biowin.org

Created in 2006, **BioWin** is the Health Cluster of Wallonia (Belgium) and its mission is to support the growth and competitiveness of the sector by bringing together stakeholders participating in R&D innovative projects and/or skills development in the fields of health biotechnology and medical technologies. **BioWin** is one of the most innovative health cluster in Europe!

Category: Public / Non-Profit Organisations

\ WALLONIA EXPORT-INVESTMENT AGENCY (AWEX)



Wallonia.be

EXPORT
INVESTMENT

Place Saintelette 2 • BE-1080 BRUSSELS
T +32 2 421 82 11
www.investinwallonia.be

Delegates: **Francis KANIA**, Director Americas • f.kania@awex.be
Yael HAUMONT, Area Manager North America • y.haumont@awex.be
Carole RENSON, AWEX Office in Montreal • carole.renson@awex-montreal.com
Aydelia GUTIERREZ, AWEX Office in Mexico • a.gutierrez@awex-wallonia.com
Jean-Pierre VASAUNE, Director Business Development • jpvasaune@gmail.com
Marc VANSTEENKISTE, Senior Area Manager North America • mvansteenkiste@investinwallonia.be
Bruno LUCIDI, Life Sciences Expert • blucidi@investinwallonia.be
Philippe LACHAPPELLE, Director Business Development and Strategic Partnerships - AWEX
Tel : +32 2 421 86 79 • p.lachapelle@awex.be

The **Wallonia Export-Investment Agency** is in charge of promoting foreign trade and attracting foreign investment. On the one hand, **AWEX** provides Wallonia-based companies with a wide range of export-oriented services; on the other hand, **AWEX** is the one-stop shop for foreign investors interested in investing in Wallonia, Belgium.

WALLONIA-BRUSSELS INTERNATIONAL



As a public administration, **Wallonia-Brussels International (WBI)** is responsible for the international relations of the Walloon Region and the Wallonia-Brussels Federation. Thanks to its exclusive capacities in various and essential areas (amongst others: education, economy, energy, culture, research, environment, etc.) and the international extension of these fields, **WBI** developed a particularly dense network abroad.

Place Saintelette 2 • BE-1080 BRUSSELS
T +32 2 421 82 11
www.wbi.be

Delegates: **Maxime VAN CAUTER**, Scientific Liaison Officer (Boston) • m.vancauter@wbi.be
Jessica MICLOTTE, Head of Unit • j.miclotte@wbi.be

\ PARTNERS WALLONIA BELGIAN DELEGATION AT BIO

BIO.BE/ESSENCIA

WALLONIA REGION TECHNOLOGY DEVELOPMENT

\ BIO.BE/ESSENCIA



Boulevard Auguste Reyers 80
BE-1030 BRUSSELS
T +32 2 238 98 44
T +32 2 238 97 11
ehanchar@essencia.be
www.essencia.be/en/bio.be

bio.be is the Belgian association of companies active in life sciences and biotechnologies. It is part of **essencia**, the Belgian federation for chemistry and life sciences industries. The mission of **bio.be/essencia** is to foster a supportive environment and a stable legal framework in line with the trend for innovation, an essential factor for:

- the economic sustainability and employment growth in the life sciences sector;
- the capability of this sector to answer major societal challenges.

Category: Public / Non-Profit Organisations

Delegates: **Frédéric DRUCK**, Secretary General • fdruck@essencia.be
Sylvie MEEKERS, Life Sciences Advisor • smeekers@essencia.be

\ WALLONIA REGION TECHNOLOGY DEVELOPMENT



Place de la Wallonie 1, Building 3
BE-5100 JAMBES
T +32 81 33 45 62
www.recherche-technologie.wallonie.be

Through its **Technology Development Department**, the **Wallonia Region** has designed a series of incentives to boost regional innovation and research and to meet the needs of all companies, from start-ups to well-established enterprises. Wallonia's R&D incentives include:

- Grants for basic industrial research (up to 80% R&D costs);
- Recoverable advances for experimental development (up to 70% R&D costs);
- Other possibilities includes grants for strategic marketing studies or patent deposits.

Delegates: **Vinciane GRIMARD**, Life Science Advisor • vinciane.grimard@spw.wallonie.be
Josée HUTSCHEMACKERS, Life Science Advisor • josee.hutschemackers@spw.wallonie.be

\ TRADE & INVESTMENT OFFICES

BOSTON

Maxime VAN CAUTER (Wallonia - Technology Attaché)

m.vancauter@wbi.be

CHICAGO

Gilles PHILIPPART DE FOY (Wallonia)

Jean-Pierre VASAUNE (Wallonia - Invest)

chicago@awex-wallonia.com

jpvasaune@investinwallonia.com

HOUSTON

Yves DUBUS (Brussels & Wallonia)

houston@awex-wallonia.com

NEW YORK

Bernard GEENEN

newyork@awex-wallonia.com

SAN FRANCISCO

Baudouin DE HEMPTINNE

sanfrancisco@awex-wallonia.com

WASHINGTON

Laurent PIERART

washington@awex-wallonia.com

MONTREAL

Michel BRICTEUX

montreal@awex-wallonia.com

TORONTO

Frank MURARI

toronto@awex-wallonia.com

MEXICO

Florence VANHOLSBECK

mexico@awex-wallonia.com

